Mobile

A multi-center, double-blind, placebo-controlled, proof-of-concept study to evaluate the efficacy and tolerability of KRP203 in patients with active subacute cutaneous lupus erythematosus

Mise à jour : Il y a 4 ans
Référence : EUCTR2010-019689-10

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To assess the preliminary clinical efficacy of oral KRP203 in clinically active, treatment refractory patients with subacute cutaneous lupus erythematosus (SCLE) after 12 weeks of treatment with KPR203 as compared to placebo. Efficacy will be assessed by using the activity score of the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI)

Critère d'inclusion

  • Subacute cutaneous lupus erythematosus, in patients who do not respond to first line therapies (i.e. antimalarials)

Liens